Synonym: (Chloracetyl) carbamic acid (3R,4S,5S,6R)-5-methoxy-4-[(2R,3R)-2-methyl-3-(3-methyl-2-butenyl)oxiranyl]-1-oxaspiro[2.5]oct-6-yl ester; AGM-1470; NSC 642492; O-Chloracetyl-carbamoyl fumagillol
Empirical Formula (Hill Notation): C19H28ClNO6
Molecular Weight: 401.88
MDL Number: MFCD00870281
Linear Formula: C19H28ClNO6
Product Type: Chemical
| assay |
≥98% (HPLC) |
| form |
solid |
| InChI |
1S/C19H28ClNO6/c1-11(2)5-6-13-18(3,27-13)16-15(24-4)12(7-8-19(16)10-25-19)26-17(23)21-14(22)9-20/h5,12-13,15-16H,6-10H2,1-4H3,(H,21,22,23)/t12-,13-,15-,16-,18+,19+/m1/s1 |
| InChI key |
MSHZHSPISPJWHW-PVDLLORBSA-N |
| originator |
Takeda |
| Quality Level |
100  |
| SMILES string |
CO[C@@H]1[C@@H](CC[C@]2(CO2)C1[C@@]3(C)O[C@@H]3CC=C(C)C)OC(=O)NC(=O)CCl |
| solubility |
DMSO: >15 mg/mL |
| storage temp. |
−20°C |
| Biochem/physiol Actions: |
Studies have reported that TNP-470 can decrease intimal neovascularization in Apo-E deficient mice. TNP-470 can also prevent tumor growth in human breast and prostate cancer cell lines. |
| Biochem/physiol Actions: |
TNP-470 is a methionine aminopeptidase-2 (MetAP-2) inhibitor, selective for MetAP-2 over MetAP11. TNP-470 is an antiangiogenic. |
| Features and Benefits: |
This compound was developed by Takeda . To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here . |
| General description: |
TNP-470 is a synthetic analogue of fumagillin. It is a natural product of Aspergillus fumigatus. TNP-470 serves as an angiogenesis inhibitor. |
| Other Notes: |
TNP-470 is hygroscopic. |
| Packaging: |
5, 25 mg in glass bottle |
| Preparation Note: |
TNP-470 is soluble in DMSO at a concentration that is greater than 15 mg/ml. |
| Hazard Codes |
Xi |
| Risk Statements |
36/37/38 |
| Safety Statements |
26 |
| RIDADR |
NONH for all modes of transport |
| WGK Germany |
WGK 2 |
| Flash Point(F) |
Not applicable |
| Flash Point(C) |
Not applicable |
| Purity |
≥98% (HPLC) |
| Storage Temp. |
−20°C |
| UNSPSC |
12352200 |
